***University of Pennsylvania Abramson Cancer Center clinical trials for patients with pancreatic cancer***

**Highlights June 26, 2014**

|  |  |  |
| --- | --- | --- |
| Treatment | Eligible patients | Status |
| Chemotherapy plus Vitamin D analogue | Patients undergoing primary surgical resection | Open at Penn\* |
| Chemotherapy plus hydoxychloroquine | Patients with metastatic cancer | Open at Penn |
| Chemotherapy plus Jak-1 inhibitor | Patients with metastatic cancer | Open at Penn and nationally |
| Engineered T cell therapy (mesothelin) | Patients with advanced metastatic cancer | Active but not recruiting |
| PARP inhibitor | Patients with BRCA1 or BRCA2 mutations and advanced metastatic disease | Open at Penn and internationally |
| Gemcitabine chemotherapy vs. FOLFIRINOX chemotherapy | Patients after primary surgical resection | Open at Penn |
| CD40 antibody with chemotherapy | Patients with resectable disease | Preclinical studies complete. Initial trial complete. Next trial to open later this winter at Penn\* |
| Radiation plus chemotherapy | Patients with borderline resectable disease, or unresectable (but not metastatic) disease | Open next month at Penn |
| Combination vaccine with or without checkpoint blockade | Patients with metastatic disease | To open later this fall at Penn\* |
| Tumor antigen vaccine | Patients in remission after surgery and adjuvant therapy | To open later this fall at Penn |
| Radiation plus checkpoint blockade | Patients with metastatic disease | Preclinical studies complete; trial design in progress |
|  |  |  |

\*Funded by one of two grants to Penn from Stand Up to Cancer